Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5854396 | Food and Chemical Toxicology | 2009 | 8 Pages |
It has been demonstrated that some strains of Bacillus coagulans can survive extremes of heat, acidity of the stomach, and bile acids, to which commonly consumed probiotics are susceptible. A toxicological safety assessment was performed on a proprietary preparation of B. coagulans - GanedenBC30⢠- a novel probiotic. Seven toxicologic studies were conducted and included: in vitro bacterial reverse mutation assay; in vitro chromosomal aberration assay; micronucleus assay in mice; acute and 90 day subchronic repeated oral toxicity studies were conducted in Wistar Crl:(WI) BR rats; acute eye and skin irritation studies were conducted in rabbits.The results of this toxicological safety assessment indicate that GanedenBC30â¢B. coagulans does not demonstrate mutagenic, clastogenic, or genotoxic effects. Furthermore, the results of the acute and 90-day subchronic oral toxicity studies in rats resulted in the conclusion of a NOAEL greater than 1000 mg/kg per day. Since the concentration of the cell mass used in the 90-day study was 1.36 Ã 1011 CFUs/g, this corresponds to 95.2 Ã 1011 CFUs for a 70 kg human and since the suggested human dose is in the range of 100 Ã 106 to 3 Ã 109 CFUs, this gives a safety factor ranging from 3173 to 95,200 times. Based upon scientific procedures and supported by history of use, GanedenBC30⢠is considered safe for chronic human consumption.